- Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- Interventions
- NNC6019-0001, Placebo (NNC6019-0001)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 49 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–268
of 268
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Heart Failure
- Interventions
- BrioVAD System, HeartMate 3
- Device
- Lead sponsor
- BrioHealth Solutions, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- HEART Camp, HEART Camp Connect
- Behavioral
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Omaha, Nebraska • Charlottesville, Virginia
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Mavacamten, Non-mavacamten symptomatic oHCM therapy
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 60
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more